POSITIVE PIVOTAL DATA FOR LIBTAYO® MONOTHERAPY IN LOCALLY ADVANCED BCC

Tagged: 

Viewing 0 reply threads
  • Author
    Posts
    • #39846
      Mary Zawadzki
      Keymaster

      FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma, read more here

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Menu